SNAP-8
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
SNAP-8 is listed as cosmetic / neuromodulating peptide.
- •Expression-line softening
Regulatory status: Cosmetic ingredient.
Structure & Properties
Compound: SNAP-8; also known as Acetyl octapeptide-3.
Pharmacologic class: Cosmetic / Neuromodulating Peptide.
Known delivery routes: Topical.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Octapeptide that competes with SNAP-25 in the SNARE complex, reducing acetylcholine vesicle docking at the neuromuscular junction.
- •Reduced depth of expression lines
- •No injection required
- •Well tolerated topically
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Manufacturer and small in-vivo cosmetic studies
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
No strict time-of-day requirement. Dose consistently at the same time daily and rotate injection sites. Follow the per-peptide dosing section above.
Potential interactions and combinations to avoid
- •Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- •Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Mild irritation
- •Modest effect vs injectable neuromodulators
Contraindications
- •Broken or inflamed skin
- •Known peptide allergy
- •Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- •Bipolar disorder, psychosis, or active mania
- •Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- •Recent intracranial haemorrhage or unstable neurologic injury
- •Broken, infected, sunburned, or actively inflamed skin
- •Concurrent prescription retinoid, chemical peel, or laser resurfacing without dermatologic guidance
- •Known copper sensitivity or Wilson's disease (copper-carrier peptides)
- •Eczema, rosacea, or perioral dermatitis in active flare
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 5–10% solution in topical formulation
Frequency: 1–2× daily topically
Cycling: Continuous topical use; 8–12 weeks to visible effect.
Topical
Cosmetic / dermal repair peptides applied directly to skin.
Serum, cream, or gel formulation. Apply to clean dry skin AM/PM. Wait 60–90 sec before layering moisturizer or sunscreen. Separate copper peptides from vitamin C / AHA by ≥12 hrs (copper is destabilized).
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is SNAP-8?
In plain words
SNAP-8 is a small chain of eight amino acids used in cosmetics. It interferes with part of the process that lets nerves release a chemical signal to muscles. Researchers study it for softening expression lines, but evidence is limited to early research and observations. It may cause mild irritation, and its effects are modest compared with injectable treatments that reduce muscle activity.
Technical definition
SNAP-8, also known as acetyl octapeptide-3, is a cosmetic neuromodulating peptide composed of eight amino acids. It competes with SNAP-25 in the SNARE complex, reducing docking of acetylcholine-containing vesicles at the neuromuscular junction. It is a cosmetic ingredient, not FDA-approved; evidence for expression-line softening is preclinical or observational.
Function
Dosing
Recommended Time of Day
Topical, morning and evening skincare routine.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Face / neck (topical) — Clean dry skin, AM and PM, before moisturizer.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous topical use; 8–12 weeks to visible effect.
Timing & Interactions
- ·Avoid stacking with peptides that share the same receptor or mechanism without clinical guidance.
- ·Avoid combining with alcohol or immunosuppressants unless cleared by a clinician.
- ·Most peptides pair safely with baseline nutrition, sleep, and resistance training.
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on SNAP-8 and sync them to Vial Lab.
Benefits
- ·Reduced depth of expression lines
- ·No injection required
- ·Well tolerated topically
Risks
- ·Mild irritation
- ·Modest effect vs injectable neuromodulators
Contraindications
- ·Broken or inflamed skin
- ·Known peptide allergy
- ·Seizure disorder or history of epilepsy (lowered seizure threshold reported for some agents)
- ·Bipolar disorder, psychosis, or active mania
- ·Concurrent MAO inhibitors, stimulants, or serotonergic agents without psychiatric oversight
- ·Recent intracranial haemorrhage or unstable neurologic injury
- ·Broken, infected, sunburned, or actively inflamed skin
- ·Concurrent prescription retinoid, chemical peel, or laser resurfacing without dermatologic guidance
- ·Known copper sensitivity or Wilson's disease (copper-carrier peptides)
- ·Eczema, rosacea, or perioral dermatitis in active flare
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Cosmetic ingredient
Veterinary Use (Pets)
No established veterinary protocol for SNAP-8. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →